Three names today, and the number three is the whole story. The market's headline reading is the best in a fortnight, but underneath it almost nothing is working: only eleven of thirty-nine industry groups are rising, every single one of the five leaders is losing speed, and the institutional rotation screen came back today with no sector worth rotating into — the first blank it has returned. So the list is capped, deliberately. Two of the three names sit in the same corner of the market, which is the mistake this desk has been paying for all month, and it is flagged rather than hidden.
Everything behind today's list refreshed normally this morning: the stock universe at 08:59 ET, the signal and breakout lists at 09:51, the sector table, the trend scan and both options tables between 10:37 and 10:41. Nothing on this page rests on yesterday's data. Two outside research feeds were unreachable, so the earnings check below was run from a different provider and no analyst or institutional sentiment is quoted today — where a number is missing it is left blank rather than filled in. All performance figures are priced live at 10:40 ET.
| Sector | Momentum | Accel | 1W | Read |
|---|---|---|---|---|
| Cloud · SKYY | +9.92 | −36.56 | +3.68% | First on momentum, last on acceleration — fastest fade in the table for a fourth session |
| Semiconductors · SOXX | +9.66 | −17.52 | +12.19% | Strongest week anywhere, but −1.66% today and 3-month still negative |
| Crypto · BLOK | +9.08 | −7.89 | +10.21% | Mildest deceleration of the five leaders, second week running |
| Software · IGV | +8.00 | −25.64 | +2.47% | Only leader green today (+0.75%); the sector behind today's top name |
| Artificial Intelligence · AIQ | +7.03 | −16.31 | +5.30% | Positive on every window, negative on the day |
| Biotechnology · XBI | +2.65 | −18.72 | +3.96% | Ninth of 39 and positive — the hunting ground for two of today's three names |
| Energy · XLE | +0.89 | −11.64 | −2.13% | Tenth of 39. Twenty-one of the thirty-nine prior picks sit here |
| Mining & Metals · XME | −0.91 | −4.22 | +0.29% | Silver, copper and gold names all fell 5%+ today; three candidates dropped on this |
Eleven of 39 sectors carry positive momentum — 28%, narrower than yesterday — and all five leaders are decelerating for a tenth straight session. The trend scan fired 13 buys against 8 sells, a far less one-sided tape than yesterday's 13:2. The single most informative line is not in the table at all: the institutional rotation screen, which normally names three or four sectors receiving flow, today named none. Strength is real but it is concentrated in one complex and it is slowing.
MRNA and OMER are both health-care names. That is the exact shape of the mistake this desk has been paying for all month: 54% of the prior book was energy, and when energy rolled over the book went with it. Two out of three is a milder version of the same concentration, and it is happening because breadth is so narrow that there is little else clearing the bar. If only one position is taken from this list, taking it from a different sector than the other two is the risk-aware choice. Sector is not a selection criterion here and has never tested as one — it is being called out as a portfolio fact, not a recommendation.
The only name in the leading complex that clears the selection rule at any scale. Application software, relative strength 85.6 against a threshold of 20, top stage score 10 on the weekly and 9 on the daily, Stage 2 for 32 weeks, and it printed a fresh 52-week high at $81.90 this morning. It appears on all three funnel lists — the Stage-2 universe, the signal screener as a buy at composite 59.1, and the breakout list. Counter-evidence: it gave the whole gain back and is now flat-to-down on the session, matching SPY exactly; volume at the morning print was thin; and no trend crossover confirms it, though the crossover scan only covers a 157-name list that does not include it — that is an absence of coverage, not an absence of signal.
The highest relative-strength reading in the entire ledger at 202, perfect stage scores of 10 and 10, on all three lists, and the only finalist green on the session in a tape where the index is down 0.6% — it is outperforming today rather than merely holding. It also carries the only matching options structure on the page. Counter-evidence: three separate caution flags. Its RSI is 73, above the overbought line; it is 81% above its 50-day average and 201% above its 200-day, so a great deal of the relative-strength number is that move; it is Stage 2B rather than a fresh 2A, at 42 weeks the most mature name here; and it too faded off its high of $192.16. Biotech is positive but is not the leadership, and it is decelerating at −18.7 like everything else.
Carries the highest composite score of the three at 60.2 and ranks second across the whole signal screener, with relative strength 66.8, a perfect weekly stage score, and only seven weeks since it entered Stage 2 — by some distance the freshest trend here. On all three lists. Counter-evidence: the smallest name on the page at $1.5bn, which means the widest spreads and the least room to exit; down on the session; no options structure of any kind available; no crossover confirmation; and its dark-pool reading is zero, which on this platform usually means no coverage rather than no accumulation. Early-stage entries have tested as neutral here, not favourable — the seven weeks is context, not an edge.
Both income tables rebuilt normally — 979 cash-secured puts across 146 names and 500 bull put spreads across 50. Only MRNA appears in either, because these screeners want large, high-volatility index names while the trend funnel produces mid-caps: two systems sharing one page. RNG and OMER have no structure available, which is the expected outcome rather than a data failure. Note that every MRNA contract carries an entry rating of hold, not buy — the screener is not endorsing the entry, only pricing it. No LEAP call surfaced, which is just as well: that structure's record on this desk is −$90.8k.
| Setup | Structure | Credit | Below spot | Delta | Annualised | Note |
|---|---|---|---|---|---|---|
| MRNA | Cash-secured put · 25 Sep · $172.50 | $0.90 | 8.1% | −0.13 | 95.2% | 2 days to expiry, IV 93. Rated hold |
| MRNA | Cash-secured put · 20 Nov · $115.00 | $2.05 | 38.7% | −0.07 | 11.2% | Far out of the money; highest composite of the MRNA set at 40.6 |
| RNG · OMER | No contracts in either table | Expected — outside the screened universe | ||||
For context only, the best-scoring premium setups today sit entirely outside the shortlist — MSTR, MU and SNDK spreads at 75–85% probability of profit. They are not desk picks and were not screened by the trend funnel; they are named so the gap between the two systems is visible rather than implied. Volatility is low (VIX 14.7, down 14.8% on the week) while sentiment reads fear at 35 — a poor premium-selling backdrop, because you are paid little to carry the risk.
| Cohort | Mean alpha | Median | Beat SPY | Best | Worst |
|---|---|---|---|---|---|
| 2026-08-31 · 7 | +0.33% | −3.40% | 3/7 | CVI +23.9% | GEN −14.6% |
| 2026-09-01 · 7 | −3.52% | +1.30% | 4/7 | CRWD +8.2% | PRGS −13.9% |
| 2026-09-02 · 3 | −12.68% | −10.87% | 0/3 | VET −10.9% | HP −16.4% |
| 2026-09-03 · 3 | −5.34% | −5.28% | 0/3 | PFE −3.6% | ZYME −7.2% |
| 2026-09-08 · 3 | −7.29% | −5.82% | 0/3 | ELPC −1.9% | MTDR −14.1% |
| 2026-09-11 · 3 | −3.72% | −4.15% | 1/3 | TEN +1.5% | UROY −8.5% |
| 2026-09-15 · 3 | −10.15% | −8.04% | 0/3 | CVE −6.8% | SM −15.6% |
| 2026-09-16 · 2 | −8.72% | −8.72% | 0/2 | MPC −6.1% | LPG −11.3% |
| 2026-09-17 · 3 | −5.80% | −7.58% | 0/3 | TRMD −2.7% | SMTC −7.6% |
| 2026-09-18 · 2 | −4.51% | −4.51% | 0/2 | ABCL −2.2% | CMBT −6.8% |
| 2026-09-21 · 3 | +4.18% | +2.79% | 2/3 | ALAB +10.0% | RBRK −0.3% |
| All 39 | −4.39% | −6.01% | 10/39 | trimmed −4.94% · ex top two −5.54% | |
Total alpha across 39 picks is −171.1 points — a mean of −4.39%, a median of −6.01%, and 10 of 39 beating the index. All three readings are worse than yesterday's −4.07 / −5.43 / −4.71. Trimming the two best and two worst leaves −4.94%; removing only the two best leaves −5.54%. The two best names between them contribute +33.9 points against a total of −171.1, so no handful of names is carrying this. The whole distribution sits below the index.
The cause has not changed and is not a selection subtlety: 21 of 39 picks — 54% — are energy names, four cohorts were entirely energy, and energy has spent the month sliding down the sector table. The encouraging line is still the last one. The 09-21 cohort was the first with no energy exposure at all and remains the best in the book at +4.18% mean, 2 of 3 beating the index, two sessions in. Two sessions is not evidence. It is the direction the sector read has pointed at for a week, and today's list continues it — nothing flagged today is an energy name.